Effect of Postoperative Ketorolac on Bone Healing After Joint Fusion

Overview

In the midst of the opioid crisis, the use of non-narcotic pain medication has garnered increased interest, particularly in the field of orthopaedic surgery, where narcotic medications are routinely prescribed postoperatively. Nonsteroidal anti-inflammatory drugs (NSAIDs) have the potential to serve as an adjunct analgesic, but many orthopaedic surgeons have viewed NSAIDs with hesitancy because of evidence that they can lead to delayed bone healing. When evaluating bone healing across different NSAID formulas, ketorolac was found to cause no delay and lead to better union rates when compared to controls and other NSAIDs, respectively. Previous studies in the orthopaedic spine and trauma literature have suggested a detrimental effect of NSAIDs, specifically ketorolac, with regards to bone healing, while others have reported no delay in healing. A recent study from our institution found no detrimental effects on the healing of ankle fractures with the use of ketorolac in the immediate postoperative period. Additionally, the use of ketorolac was associated with less reliance on narcotic pain medications. The purpose of this prospective randomized study is to evaluate the use of ketorolac on postoperative pain, opioid requirements, patient satisfaction, complication/reoperation rates, and delayed and/or nonunion rates in patients undergoing fusion of their first metatarsophalangeal joint (1st MTPJ) for treatment of end-stage arthritis.

Full Title of Study: “Prospective Randomized Study Evaluating the Effect of Postoperative Ketorolac on Bone Healing and Opioid Consumption After First Metatarsophalangeal Joint Fusion”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Single (Participant)
  • Study Primary Completion Date: December 31, 2021

Interventions

  • Procedure: great toe (1st metatarsophalangeal joint) fusion
    • Great Toe joint fusion surgery
  • Drug: IV Ketorolac
    • Participants will receive 30mg of intravenous (IV) ketorolac will be given during surgery
  • Drug: Ketorolac Pill
    • Participants will receive 20 tablets of 10mg ketorolac, with instructions to take 1 tablet orally every 6 hours for pain
  • Drug: 5/325mg Oxycodone-Acetaminophen
    • Participants will receive 30 tablets of 5/325mg oxycodone-acetaminophen with instructions to take 1 or 2 tablets by mouth every 4 to 6 hours as needed for pain
  • Drug: Aspirin 81Mg Ec Tab
    • Participants will receive 81 mg aspirin twice daily as a preventive measure against deep venous thrombosis (DVT)

Arms, Groups and Cohorts

  • Active Comparator: Ketorolac administration
    • Participants who have surgery for great toe (1st metatarsophalangeal joint) fusion will receive 30 mg of IV ketorolac during surgery as well as 20 mg ketorolac pills to take after surgery for pain
  • Active Comparator: No Ketorolac administration
    • Participants who have surgery for great toe (1st metatarsophalangeal joint) fusion will receive the standard treatment of 30 tablets of oxycodone-acetaminophen to take as needed for pain

Clinical Trial Outcome Measures

Primary Measures

  • Postoperative Pain
    • Time Frame: 7 days
    • Participants will be asked to complete the Visual Analog Scale for Pain Survey to measure postoperative pain
  • Satisfaction with pain management
    • Time Frame: 7 days
    • This will be measured using the 6-point Likert scale (very dissatisfied, dissatisfied, slightly dissatisfied, slightly satisfied, satisfied, very satisfied)
  • Participant Perception of Pain
    • Time Frame: 7 days
    • This will be measured using a 5-point Likert scale (never, almost never, often, almost always, always)

Participating in This Clinical Trial

Inclusion Criteria

  • Patients over the age of 18 undergoing outpatient primary 1st MTPJ fusion by a fellowship-trained foot and ankle orthopaedic surgeon at the Rothman Orthopaedic Institute Exclusion Criteria:

  • Patients undergoing revision 1st MTPJ fusion; – Patients with any allergies to any study medication; – Patients with documented chronic narcotic use; – Patients with renal insufficiency, as defined by history and preoperative creatinine level (Cr ≥ 2.1 mg/dl); – Patients who are pregnant; – Patients undergoing inpatient procedure.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Rothman Institute Orthopaedics
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.